Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia

28-Nov-2008 - Denmark

H. Lundbeck A/S expands its pipeline of pharmaceuticals in clinical development by initiating phase II trials with the compound Lu AE58054. The compound is a new pharmaceutical candidate in Lundbeck's portfolio and represents a novel approach to the treatment of schizophrenia.

Lu AE58054 has shown positive results in a number of preclinical trials, which documented the compound's ability to improve cognition. Affecting other areas of the brain than traditional anti-psychotics, the compound has an effect that breaks with tradition. In this way, Lu AE58054 complements the existing anti-psychotics by improving the general clinical efficacy of the overall treatment. Consequently, Lundbeck expects that Lu AE58054 will improve the daily functioning of the patients and for example improve their ability to solve practical problems in their daily lives.

Based on the positive preclinical data and positive outcomes of phase I trials in healthy individuals, Lundbeck has now launched a phase II trial with two treatment groups of 60 patients each. The first group will receive treatment with risperidone and placebo, while the other will receive risperidone and Lu AE58054. The treatment period will run for three months. The trial has just been initiated, and preliminary results are expected by the end of 2009.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance